Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

Adjusting for these factors, Biocon’s Q3 FY25 revenue saw a 10 per cent year-on-year growth. The company’s net research and development investments for the quarter stood at Rs 199 crore, representing ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

BENGALURU: Biocon Foundation has unveiled a breathtaking public art spectacle, turning over 50 Metro pillars between Huskur ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

The share price of Biocon has fallen more than 5% in the last five trading days. (Image: Freepik) The share price of Biocon rose almost 4% to an intra-day high of Rs 370.90 despite reporting a fall of ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

There is market share gain compared to last year. Any biosimilar might be able to take on a four-five or six player market, ...

Biocon Foundation transforms metro pillars into art celebrating Bengaluru's unsung heroes, merging heritage with urban landscape.